Related Experiment Video

Updated: Jul 12, 2026

A Syngeneic Mouse Model of Metastatic Renal Cell Carcinoma for Quantitative and Longitudinal Assessment of Preclinical Therapies
06:38

A Syngeneic Mouse Model of Metastatic Renal Cell Carcinoma for Quantitative and Longitudinal Assessment of Preclinical Therapies

Published on: April 12, 2017

[Is there an indication for neoadjuvant or adjuvant systemic therapy in renal cell cancer?]

C Doehn1, A S Merseburger, D Jocham

  • 1Klinik und Poliklinik für Urologie, Universitätsklinikum Schleswig-Holstein (UK S-H), Campus Lübeck, Ratzeburger Allee 160, 23538 Lübeck. doehn@medinf.mu-luebeck.de

Der Urologe. Ausg. A
|September 7, 2007
PubMed

Insights

Kidney cancer has a poor prognosis, with surgery as primary treatment. Adjuvant therapies like vaccines show promise for improving survival, unlike earlier cytokine treatments with significant side effects.

Area of Science:

  • Urology
  • Oncology
  • Neoadjuvant and Adjuvant Therapies

Context:

  • Kidney cancer presents a significant challenge in urological oncology due to its poor prognosis.
  • Tumor size >4-5 cm correlates with increased risk of postoperative relapse, necessitating further therapeutic strategies.
  • Current treatment paradigms primarily involve surgical tumor removal.

Purpose:

  • To review the landscape of neoadjuvant and adjuvant therapies for kidney cancer.
  • To evaluate the efficacy and safety of previously investigated and ongoing therapeutic approaches.
  • To identify promising future directions in kidney cancer treatment.

Summary:

  • No Phase III trials on neoadjuvant kidney cancer therapy are published.
  • Five Phase III trials on adjuvant therapy have been published, with four using cytokine-based treatments (interferon-alpha, interleukin-2) showing no positive outcomes and significant side effects.
  • One trial demonstrated improved progression-free and overall survival using an autologous tumor cell vaccine (Reniale) with minimal side effects.
  • Ongoing trials explore combinations of cytokines, vaccines, and novel agents like tyrosine kinase inhibitors (sunitinib, sorafenib).

Impact:

  • Adjuvant autologous tumor cell vaccines represent a potential breakthrough in kidney cancer treatment, offering improved survival with a favorable safety profile.
  • Future research directions include evaluating novel combinations and targeted therapies like tyrosine kinase inhibitors.
  • The findings highlight the need for more effective adjuvant strategies to improve outcomes for patients with high-risk kidney cancer.

More Related Videos

Modeling Spontaneous Metastatic Renal Cell Carcinoma (mRCC) in Mice Following Nephrectomy11:27

Modeling Spontaneous Metastatic Renal Cell Carcinoma (mRCC) in Mice Following Nephrectomy

Published on: April 29, 2014

The Use of Reverse Phase Protein Arrays (RPPA) to Explore Protein Expression Variation within Individual Renal Cell Cancers12:22

The Use of Reverse Phase Protein Arrays (RPPA) to Explore Protein Expression Variation within Individual Renal Cell Cancers

Published on: January 22, 2013

Related Concept Videos

Treatment Resistent Cancers02:56

Treatment Resistent Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Tumor Immunotherapy01:27

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
Acute Kidney Injury IV: Diagnostic Studies and Prevention01:30

Acute Kidney Injury IV: Diagnostic Studies and Prevention

Accurate diagnosis and effective prevention are critical in managing Acute Kidney Injury (AKI), which is linked to high mortality rates ranging from 10% to 80%. Timely recognition of at-risk patients and careful monitoring can significantly reduce the likelihood of kidney damage.Diagnostic Assessments:The diagnostic process starts with a comprehensive medical history to identify prerenal, intrarenal, and postrenal causes.Prerenal causes, such as dehydration, hypotension, or blood loss, should...
Chronic Kidney Disease III: Interprofessional Care01:28

Chronic Kidney Disease III: Interprofessional Care

Chronic kidney disease (CKD) requires collaborative and comprehensive management. CKD progresses through stages and can lead to end-stage kidney disease (ESKD) if untreated. Interprofessional collaboration and patient education are crucial, enabling patients to manage their health and improve their quality of life.Diagnostic approach for chronic kidney diseaseThe diagnosis of CKD primarily focuses on the glomerular filtration rate (GFR), which assesses kidney function by measuring how well...